Clinical trial NCT00669721 - References

Hemodialysis — OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis

Citation(s)

•   Collin-Osdoby P
  Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004 Nov 26;95(11):1046-57. Review.
•   Deruelle P, Coulon C
  The use of low-molecular-weight heparins in pregnancy--how safe are they? Curr Opin Obstet Gynecol. 2007 Dec;19(6):573-7. Review.
•   Folwarczna J, Sliwinski L, Janiec W, Pikul M
  Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. Pharmacol Rep. 2005 Sep-Oct;57(5):635-45.
•   Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordøy A
  Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost. 1996 Nov;76(5):703-9.
•   Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y
  Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone. 2007 Aug;41(2):165-74. Epub 2007 May 5.
•   Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG
  A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 1997 May 1;89(9):3236-42.
•   Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, Nihei H
  Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004 Jul;19(7):1886-9. Epub 2004 May 5.
•   Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, Mito S, Soe NN, Yoshizumi M
  Role of osteoprotegerin in arterial calcification: development of new animal model. Arterioscler Thromb Vasc Biol. 2007 Sep;27(9):2058-64. Epub 2007 Jul 5.
•   Pettilä V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R
  Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002 Feb;87(2):182-6.
•   Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM
  Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int. 2008 Feb;73(4):384-90. Epub 2007 Nov 28. Review.
•   Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A
  Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002 Oct 15;100(8):3002-7.
•   Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D
  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochem Biophys Res Commun. 2006 Aug 25;347(2):460-7. Epub 2006 Jun 30.
•   Valentin S, Larnkjer A, Ostergaard P, Nielsen JI, Nordfang O
  Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res. 1994 Jul 15;75(2):173-83.
•   Vega D, Maalouf NM, Sakhaee K
  CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007 Dec;92(12):4514-21. Epub 2007 Sep 25. Review.
•   Vescini F, Buffa A, Sinicropi G
  Osteoprotegerina RANKL e RANK nella regolazione dell'ostoclastogenesi. Riv It Biol Med 22: 64-67, 2002.
•   Vik A, Brodin E, Sveinbjørnsson B, Hansen JB
  Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007 Jul;98(1):148-54.
•   Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR
  Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005 Aug;204(2):714-23.

Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients

Details for clinical trial NCT00669721